SK Biopharm, 336,866 Shares Net Bought by Individuals Over Last 5 Days... Stock Price at 103,500 KRW (-0.96%)

As of 2:31 PM on the 26th, SK Biopharm is trading at 103,500 KRW, down 0.96% from the previous day. The trading volume is 247,802 shares, which is about 76.25% of the previous day's volume.

On March 23, researcher Gu Ja-yong from DB Financial Investment stated, "The initial sales performance of the new drug launched by SK Biopharm should be viewed with expectations rather than disappointment. Considering the characteristics of CNS (central nervous system) drugs, the initial sales of Xcopri have exceeded expectations even amid the COVID-19 situation. SK Biopharm, which has succeeded in new drug development and is building a global value chain, is gradually becoming closer to UCB (a Belgium-based pharmaceutical company focused on CNS) rather than a simple bio company. Both performance and stock price are expected to trend upward. Do not miss the current lowest point since listing." He set the target price for SK Biopharm at 140,000 KRW.

Over the past five days, individual investors have net purchased 336,866 shares of SK Biopharm, while foreigners and institutions have net sold 322,390 shares and 11,591 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.